Valproate, bipolar disorder and polycystic ovarian syndrome

Bipolar Disorders

Volumn 5, Issue 1, 2003, Pages 28-35

  McIntyre, Roger S ^a   Mancini, Deborah A ^a   McCann, Sonia ^a   Srinivasan, Janaki ^a   Kennedy, Sidney H ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bipolar; Hyperandrogenism; Leptin; Menstrual cycle; Polycystic ovarian syndrome; Valproic acid

Indexed keywords

ANDROSTENEDIONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CONTRACEPTIVE AGENT; ESTRADIOL; FOLLITROPIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; VALPROIC ACID;

ADULT; AMENORRHEA; ANAMNESIS; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; ENDOCRINE SYSTEM EXAMINATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; METABOLIC DISORDER; OBESITY; OLIGOMENORRHEA; OVARY CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL;

ADOLESCENT; ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; VALPROIC ACID;

EID: 0038445340     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2003.00009.x     Document Type: Article

References (40)

1. Reaven G, Chen Y. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1998; 4: 639-652.
2. Chappell KA, Markowitz JS, Jackson CW. Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 1999; 33: 1211-1216.
3. Rasgon NL, Altshuler LL, Gudeman D et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000; 61: 173-178.
4. Rosenfield RL. Current concepts of polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol 1997; 11: 307-333.
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
6. Taylor A. Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. Am J Obstet Gynecol 1998; 179: S94-S100.
7. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
8. Scarpitta AM, Sinagra D. Polycystic ovary syndrome. an endocrine and metabolic disease. Gynecol Endocrinol 2000; 14: 392-395.
9. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579-584.
10. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-993.
11. Pugeat M, Ducluzeau PH. Insulin resistance, polycystic ovary syndrome and metformin. Drugs 1999; 58 (Suppl. 1): 41-46; Discussion 75-82.
12. Sanaka M, Iwamoto Y. Troglitazone for treatment of polycystic ovary syndrome. Nippon Rinsho 2000; 58: 465-470.
13. Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998: 40(Jul): S3-S8.
14. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999; 71: 323-327.
15. Azziz R, Ehrmann D, Legro RS et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632.
16. Sachs G. Medication treatment bipolar disorder 2000: the expert consensus guideline series, Postgraduate Medicine: A special report, 2000.
17. Isojarvi JI, Rattya J, Myllyla VV et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-451.
18. Genton P, Bauer J, Duncan S et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42: 295-304.
19. Gracious BL, Wisner KL. Valproate and the risk of hyperandrogenism. Bipolar Disorders 2000; 3: 50.
20. Piontek CM, Wisner KL. Appropriate clinical management of women taking valproate. J Clin Psychiatry 2000; 61: 161-163.
21. Soares JC. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries. Bipolar Disord 2000; 2: 37-41.
22. O'Donnovan C, Kusumaker V, Graves J, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. Bipolar Disord 1999; 1 (Suppl. 1): 45.
23. Vainionpaa LK, Rattya J, Knip M et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444-450.
24. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61: 179-184.
25. McIntyre R, McCann S, Kennedy S. Antipsychotic metabolic effects. weight gain, diabetes and hypertriglyceridemia. Can J Psychiatry 2001; 46: 273-281.
26. Ginsberg DNS. Effects of mood stabilizers on weight. Primary Psychiatry 2000; 7: 49-54.
27. Yanovski JA, Yanovski SZ. Recent advances in basic obesity research. Jama 1999; 282: 1504-1506.
28. Yamamoto N, Li QL, Mita S, Morisawa S, Inoue A. Inhibition of thyroid hormone binding to the nuclear receptor by mobilization of free fatty acids. Horm Metab Res 2001; 33: 131-137.
29. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. Tremor, weight gain, psychologlical complaints. Acta Psychiatr Scand 1988; 78: 434-441.
30. Berum L, Astrup A, Gram L. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 660-670.
31. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-1388.
32. Popovic V, Spremovic S. The effect of sodium valproate on luteinizing hormone secretion in women with polycystic ovary disease. J Endocrinol Invest 1995; 18: 104-108.
33. Murialdo G, Galimberti CA, Gianelli MV et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998; 21: 52-58.
34. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489.
35. Verotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230-232.
36. Hebebrand J, Blum WF, Barth N et al. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. Mol Psychiatry 1997; 2: 330-334.
37. Herzog A. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia 1991; 32 (Suppl. 6): 27-33.
38. Gross A, Devinsky O, Westbrook LE, Wharton AH, Alper K. Psychotropic medication use in patients with epilepsy: effect on seizure frequency. J Neuropsychiatry Clin Neurosci 2000; 12: 458-464.
39. Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 2001; 86: 2903.
40. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem 1998; 44: 2178-2182.